Monoamine oxidase and neurodegeneration: Mechanisms, inhibitors and natural compounds for therapeutic intervention

被引:11
作者
Banerjee, Chayan [1 ,2 ]
Tripathy, Debasmita [3 ]
Kumar, Deepak [4 ]
Chakraborty, Joy [1 ]
机构
[1] CSIR Indian Inst Chem Biol, Cell Biol & Physiol Div, Kolkata 700032, India
[2] Acad Sci & Innovat Res AcSIR, Ghaziabad 201002, India
[3] Netaji Nagar Coll Women, Dept Zool, Kolkata 700092, India
[4] CSIR Indian Inst Chem Biol, Organ & Med Chem Div, Kolkata 700032, India
关键词
Monoamine oxidase; Reactive oxygen species; Mitochondrial aberration; Neurological disorders; Parkinson's disease; Monoamine oxidase inhibitors; MAO-B INHIBITOR; HYDROGEN-PEROXIDE PRODUCTION; PARKINSONS-DISEASE PATIENTS; PLACEBO-CONTROLLED TRIAL; DELAYED-START TRIAL; POST-HOC ANALYSES; DOUBLE-BLIND; ALZHEIMERS-DISEASE; OXIDATIVE STRESS; PARGYLINE HYDROCHLORIDE;
D O I
10.1016/j.neuint.2024.105831
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Mammalian flavoenzyme Monoamine oxidase (MAO) resides on the outer mitochondrial membrane (OMM) and it is involved in the metabolism of different monoamine neurotransmitters in brain. During MAO mediated oxidative deamination of relevant substrates, H2O2 is released as a catalytic by-product, thus serving as a major source of reactive oxygen species (ROS). Under normal conditions, MAO mediated ROS is reported to propel the functioning of mitochondrial electron transport chain and phasic dopamine release. However, due to its localization onto mitochondria, sudden elevation in its enzymatic activity could directly impact the form and function of the organelle. For instance, in the case of Parkinson's disease (PD) patients who are on L-dopa therapy, the enzyme could be a concurrent source of extensive ROS production in the presence of uncontrolled substrate (dopamine) availability, thus further impacting the health of surviving neurons. It is worth mentioning that the expression of the enzyme in different brain compartments increases with age. Moreover, the involvement of MAO in the progression of neurological disorders such as PD, Alzheimer's disease and depression has been extensively studied in recent times. Although the usage of available synthetic MAO inhibitors has been instrumental in managing these conditions, the associated complications have raised significant concerns lately. Natural products have served as a major source of lead molecules in modern-day drug discovery; however, there is still no FDAapproved MAO inhibitor which is derived from natural sources. In this review, we have provided a comprehensive overview of MAO and how the enzyme system is involved in the pathogenesis of different age-associated neuropathologic conditions. We further discussed the applications and drawbacks of the long-term usage of presently available synthetic MAO inhibitors. Additionally, we have highlighted the prospect and worth of natural product derived molecules in addressing MAO associated complications.
引用
收藏
页数:19
相关论文
共 329 条
[11]   Oxidative Stress and Major Depression [J].
Bajpai, Ashutosh ;
Verma, Akhilesh Kumar ;
Srivastava, Mona ;
Srivastava, Ragini .
JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, 2014, 8 (12) :CC4-CC7
[12]   Metabolism of monoamine oxidase inhibitors [J].
Baker, GB ;
Urichuk, LJ ;
McKenna, KF ;
Kennedy, SH .
CELLULAR AND MOLECULAR NEUROBIOLOGY, 1999, 19 (03) :411-426
[13]   Lack of efficacy of moclobemide or imipramine in the treatment of recurrent brief depression: results from an exploratory randomized, double-blind, placebo-controlled treatment study [J].
Baldwin, David S. ;
Green, Mary ;
Montgomery, Stuart A. .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2014, 29 (06) :339-343
[14]   α-Viniferin, a dietary phytochemical, inhibits Monoamine oxidase and alleviates Parkinson's disease associated behavioral deficits in a mice model [J].
Banerjee, Chayan ;
Barman, Raju ;
Darshani, Priya ;
Pillai, Meghana ;
Ahuja, Sanchi ;
Mondal, Rupsha ;
Pragadheesh, V. S. ;
Chakraborty, Joy ;
Kumar, Deepak .
NEUROCHEMISTRY INTERNATIONAL, 2024, 174
[15]  
Banerjee C, 2022, FOOD FUNCT, V13, P6545, DOI [10.1039/d2fo00734g, 10.1039/D2FO00734G]
[16]  
BARBER JM, 1962, BRIT HEART J, V24, P192
[17]   A randomized clinical trial to evaluate the effects of rasagiline on depressive symptoms in non-demented Parkinson's disease patients [J].
Barone, P. ;
Santangelo, G. ;
Morgante, L. ;
Onofrj, M. ;
Meco, G. ;
Abbruzzese, G. ;
Bonuccelli, U. ;
Cossu, G. ;
Pezzoli, G. ;
Stanzione, P. ;
Lopiano, L. ;
Antonini, A. ;
Tinazzi, M. .
EUROPEAN JOURNAL OF NEUROLOGY, 2015, 22 (08) :1184-1191
[18]   Role of Monoamine Oxidase Activity in Alzheimer's Disease: An Insight into the Therapeutic Potential of Inhibitors [J].
Behl, Tapan ;
Kaur, Dapinder ;
Sehgal, Aayush ;
Singh, Sukhbir ;
Sharma, Neelam ;
Zengin, Gokhan ;
Andronie-Cioara, Felicia Liana ;
Toma, Mirela Marioara ;
Bungau, Simona ;
Bumbu, Adrian Gheorghe .
MOLECULES, 2021, 26 (12)
[19]  
BENADY DR, 1965, DIS NERV SYST, V26, P792
[20]   THE ANTICONVULSANT FCE-26743 IS A SELECTIVE AND SHORT-ACTING MAO-B INHIBITOR DEVOID OF INDUCING PROPERTIES TOWARDS CYTOCHROME-P450 DEPENDENT TESTOSTERONE HYDROXYLATION IN MICE AND RATS [J].
BENEDETTI, MS ;
MARRARI, P ;
COLOMBO, M ;
CASTELLI, MG ;
ARAND, M ;
OESCH, F ;
DOSTERT, P .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1994, 46 (10) :814-819